8 / 20
Page 28
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
Biography
Tamer B Bayomy has completed his PhD from Cairo University.
He was serving as an Expert /Lecturer for the IAEA since 2010.
He was granted as a Member of the American Board in Radio-
pharmacy in June 2014. He is the Head of the Cyclotron De-
partment, International Medical Centre, Cairo, Egypt since 2016.
He worked as the Head of Cyclotron in King Hamad University
Hospital, Bahrain from 2012 to 2016. He also has worked as
Senior Radiopharmacist and an Acting Cyclotron Head (2005-
2012) in King Fahd Specialist Hospital, Saudi Arabia.
tamirbayomy@yahoo.comPET radiopharmaceuticals production facilities, planning and
operation challenges
Tamer B Bayomy
International Medical Centre, Egypt
Tamer B Bayomy, J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-002
C
yclotron facilities are relatively long lived solutions. Having a production facility
complying with the international standards of good manufacturing practice
(GMP) can be only achieved by a well-planed road map. The scope of services
provided by the facility and how much it is incorporated in the national research
and production activities is defining how it should be planned and operated. The
production facility can’t be limited only to the cyclotron products but should be
designed to accommodate all PET and some SPECT radionuclide production
technologies to act as a central nuclear pharmacy for the local area.